Role of rhubarb and α-keto analogues of essential amino acids supplementation in halting progression of chronic kidney disease

Irfan Ahmad Khan, Mohammad Nasiruddin, Shahzad F. Haque, Rahat A. Khan


Background: Chronic kidney disease (CKD) is an emerging chronic disease due to rapidly increasing incidence of diabetes and hypertension worldwide. Newer drugs are being searched which can stop nephron damage and are cost effective. This study was undertaken to compare the efficacy and safety profile of rhubarb and α-keto analogues of essential amino acids supplementation in patients of chronic kidney disease.

Methods: A prospective comparative study was conducted in patients of chronic kidney disease attending Renal Clinic of a tertiary care centre. Randomization of patients was done into three interventional groups: conservative management along with placebo was given in first group (Control); conservative management along with Rhubarb capsule (350 mg, thrice daily) was given in second group (Rhubarb) and conservative management along with α-keto analogues of essential amino acids (600 mg, thrice daily) was given in third group (KAA). The treatment was given for 12 weeks. Clinical and biochemical parameters were assessed at 0, 4, 8 and 12 weeks of treatment.

Results: Patients of all three groups showed gradual improvement in clinical features and biochemical parameters as compared to their pre-treated values which was more marked in KAA supplemented group. There was reduction in: fasting blood glucose (12.51%, 19.15% and 20.78%), PPBG (14.80%, 19.00% and 20.89%), serum creatinine (25.00%, 30.54% and 39.52%), blood urea (25.55%, 33.64% and 38.09%), and 24-hour total urine protein (TUP) (19.80%, 30.18% and 38.34%) in Group I, II and III respectively. There was increase in: haemoglobin level (12.64%, 14.99% and 19.77%), 24-hour total urine volume (TUV) (19.41%, 28.82% and 33.32%) and GFR (22.6%, 46.5% and 49.2%) in Group I, II and III respectively. Rhubarb and KAA supplementations were safe and well-tolerated.

Conclusions: KAA is more effective than Rhubarb as add on therapy with conservative management in patients of chronic kidney disease.


α-keto analogues of essential amino acids, Conservative management, Chronic kidney disease, Rhubarb

Full Text:



Bargman JM, Skorecki K. Chronic Kidney Disease. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J ed. Harrison’s Principles of Internal Medicine. 18th ed. New York: The McGraw-Hill Companies. Inc. 2012.

Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: Epidemiology, social, and economic implications. Kidney Int. 2005;68(98):S7-10.

Singh AK, Farag YMK, Mittal BV, Subramanian KK, Reddy SRK, Acharya VN, et al. Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and early evaluation of kidney disease) study. BMC Nephrology. 2013;14:114.

Gao LL, Xu XD, Nang HJ, Yang JS, Chen SL. Chemical constituents in Rheum tanguticum. Chin Tradit Herb Drugs. 2011;42(3):443-6.

Choi SB, Ko BS, Park SK, Jang JS, Park S. Insulin sensitizing and alpha-glucoamylase inhibitory action of sennosides, rhein and rhaponticin in Rhein Rhizoma. Life Sci. 2006;78(9):934-42.

Gao Q, Qin WS, Jia ZH, Zheng CH, Li LS, Liu ZH. Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with diabetic nephropathy. Planta Med. 2010;76(1):27-33.

Zhou XM, Chen QH. Studies on Chinese Rhubarb: XXII, inhibitory effect of anthraquinone derivatives on Na+-K+-ATPase of rabbit renal medulla and their diuretic action. Acta Pharm Sinica. 1988; 23:17-20.

Khan IA, Nasiruddin M, Haque SF, Khan RA. Evaluation of Rhubarb Supplementation in Stages 3 and 4 of Chronic Kidney Disease: A Randomized Clinical Trial. International Journal of Chronic Diseases. 2014;2014:789340.

Chang JH, Dong KK, Jung TP, Kang EW, Yoo TH, Kim BS, Choi KH, et al. Influence of ketoanalogs supplementation on the progression in chronic kidney disease patients who had training on low-protein diet. Nephrology. 2009;14(8):750-7.

Khan IA, Nasiruddin M, Haque SF, Khan RA. Clinical evaluation of efficacy and safety of α-keto analogs of essential amino acids supplementation in patients of chronic kidney disease. Int J Basic Clin Pharmacol 2014;3(3):484-9.

Teplan V. Supplements of Keto Acids in patients with chronic renal failure. Nefroloji Dergisi 2004;13(1):3-7.

Aparicio M, Gin H, Potaux L, Bouchet JL, Morel D, Aubertin J. Effect of a ketodiet on glucose tolerance and tissue insulin sensitivity. Kidney Int Suppl. 1989;27:S231-5.

Chen JB, Cheng BC, Kao TW. A comparison of progression of chronic renal failure: low dose vs standard dose ketoacids. Kidney Res Clin Pract. 2012;31(2):A24.

Walser M, Coulter W, Dighe S, Crantz FR. The effect of keto-analogues of essential amino acids in severe chronic uremia. J Clin Invest. 1973;52(3):678-90.

Mitch WE, Abras E, Walser M. Long-term effects of a new ketoacid-amino acid supplement in patients with chronic renal failure. Kidney Int. 1982; 22(1):48-53.

Qiu HY, Liu F, Zhao LJ, Huang SM, Zuo C, Zhong H et al. Comparison of the effects of alpha-keto/ amino acid supplemented low protein diet and diabetes diet in patients with Diabetic nephropathy. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012; 43(3):425-8.

Chen N, Jin Y, Ren H, Xu J, Shen P, Huang X. Anti-inflammatory effects of low protein diet supplemented with keto-amino acid in the treatment of type 2 diabetic nephropathy. Kidney Research and Clinical Practice, 2012;31(2):A24.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm.1992;49(9):2229-32.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27(5):1047-53.

Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens. 2004;18(2):73-8.

Kher V. End-stage renal disease in developing countries. Kidney Int. 2002;62(1):350-62.

Rajapurkar MM, John GT, Kirpalani AL, Abraham G, Agarwal SK, Almeida AF et al. What do we know about chronic kidney disease in India: first report of the Indian CKD registry. BMC Nephrol. 2012;13:10.

Ye R, Li Y, Sun D. Clinical study of the therapeutic effects of rhubarb as a main drug in the treatment of chronic renal failure. Chinese Journal of Integrated Traditional and Western Medicine. 1995;1(2):104-7.

Sanada H. Study on the clinical effect of rhubarb on nitrogen-metabolism abnormality due to chronic renal failure and its mechanism. Nihon Jinzo Gakkai Shi. 1996;38(8):379-87.

Liu ZH, Li LS, Hu WX, Zhou H. Effect of Emodin on c-myc proto-oncogene expression in mesangial cells. J Nephrol Dial Transplant, 1992;1:27-30.

Hu WX, Li LS, and Yao J. Rheum officinale inhibited the production of interleukin 1 and tumor necrosis factor by macrophages. Bull Jinling Hosp 1991;4:404-7.

Liu ZH, Li LS, Hu WX, Zhou H. Effect of IL-6 on c-myc proto-oncogene expression in human mesangial cells and the down regulation by Emodin. J Nephrol Dial Transplant. 1993;2:58-61.

Li L. End stage renal disease in china. Kidney International. 1996;49:287-301.

Li F, Wang SC, Wang X, Ren QY, Wang W, Shang GW, et al. Novel exploration of cathartic pharmacology induced by rhubarb. China J Chin Mater Med. 2008;33(4):481-4.

Richards P, Metcalfe-Gibson A, Ward EE, Wrong O, Houghton BJ. Utilisation of ammonia nitrogen for protein synthesis in man, and the effect of protein restriction and uraemia. Lancet. 1967 ;290(7521):845-9.

Ell S, Fynn M, Richards P, Halliday D. Metabolic studies with keto acid diets. The Am J Clin Nutr. 1978;31(10):1776-83.